Journal: International journal of oncology

Article Title: Long noncoding RNA AFAP1-AS1 indicates a poor prognosis of hepatocellular carcinoma and promotes cell proliferation and invasion via upregulation of the RhoA/Rac2 signaling.

doi: 10.3892/ijo.2016.3385

Figure Lengend Snippet: Figure 2. AFAP1-AS1 knockdown downregulates RhoA/Rac2 signaling in HCC cells. (A) Expression level of AFAP1-AS1 was detected by real-time PCR assay after HCC cell lines (SMCC-721 and HepG2) were infected with lentivirus-mediated si-AFAP1-AS1 for 24 h (**P<0.01). (B) Protein expression levels of RhoA and Rac2 were detected by western blot assay after AFAP1-AS1 knockdown.

Article Snippet: All antibodies including RhoA, Rac2, PCNA, MMP-9, CyclinD1 and Bax were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Techniques: Knockdown, Expressing, Real-time Polymerase Chain Reaction, Infection, Western Blot

Journal: Oncotarget

Article Title: Gambogic acid suppresses cancer invasion and migration by inhibiting TGFβ1-induced epithelial-to-mesenchymal transition

doi: 10.18632/oncotarget.15449

Figure Lengend Snippet: A549 cells were treated with the indicated concentrations of GA and TGFβ1 for 24 h. (A) A549 cells were treated with the indicated concentrations of GA and TGFβ1 for 24 h. The expression of E-cadherin, vimentin, N-cadherin, MMP9, and RAC1 proteins in the cells was analyzed by western blotting using specific antibodies. An anti-β-actin antibody was used to check equivalent protein loading. (B) The expression of transcription factors TWIST1 and SNAIL was measured with western blotting. The values under each lane indicate the relative densities of the bands normalized to that of β-actin. (C) E-cadherin, vimentin, N-cadherin, MMP9, RAC1 and TWIST1 and SNAIL mRNAs were measured with real-time PCR. β-Actin was used as the internal control. The relative levels were calculated as the ratio of the relative biomarker mRNA to β-actin mRNA. Each experiment was performed at least three times. *p < 0.05 compared with the TGFβ1-treated group; **p < 0.01 compared with the TGFβ1-treated group.

Article Snippet: SIS3, and primary antibodies directed against IκBα, β-actin, MMP-9, RAC1, TWIST1, p38, p-p38 and NF-κB (p65) were from Santa Cruz Biotechnology (Santa Cruz, CA), antibodies directed against phosphorylated IκBα (p-IκBα; Ser32), MEK, p-MEK, IKKα, and p-IKKα/β (Ser176/180) were from Cell Signaling Technology (Danvers, MA), antibodies directed against transferritin receptor, SMAD4, lamin A, SNAIL, SMAD3, p-SMAD3(T179), E-cadherin, N-cadherin, TWIST1 and vimentin were from Bioworld (Bioworld, MN).

Techniques: Expressing, Western Blot, Real-time Polymerase Chain Reaction, Control, Biomarker Discovery

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Article Title: Elucidating the mechanisms of Buyang Huanwu Decoction in treating chronic cerebral ischemia: A combined approach using network pharmacology, molecular docking, and in vivo validation.

doi: 10.1016/j.phymed.2024.155820

Figure Lengend Snippet: Fig. 4. Molecular docking results. (A) Molecular docking of ALB and Beta-Sitosterol. (B) Molecular docking of AKT1 and Kaempferol. (C) Molecular docking of IL-6 and Quercetin. (D) Molecular docking of IL-1β and Beta-Sitosterol. (E) Molecular docking of TP53 and Quercetin. Note: The rod model in the molecular docking result diagram is the active molecule, the green rod structure is the carbon skeleton of small molecules, the red dot is the oxygen atom, the white dot is the hydrogen atom, and the dotted line is the chemical bond formed between the active ingredient and the amino acid residue.

Article Snippet: The following reagents were used: Nimodipine Tablets (Bayer Healthcare Company Ltd., BJ71756), Methanol (CNW Technologies, CAS: 67–56–1), Acetonitrile (CNW Technologies, CAS: 75–05–8), Formic acid (SIGMA, CAS: 64–18–6), 2-Chloro-L-phenylalanine (Shanghai Hengbai Biotech Co., Ltd, CAS: 103616–89–3), isoflurane (Shenzhen Reward Biotechnology Co., Ltd., R510–22–10), ampicillin sodium (Beijing Solarbio Science & Technology Co., Ltd, A8180), Universal tissue fixative (Servicebio, G1101), HE dye kit (Servicebio, G1003), Nissl staining (Servicebio, G1036), Myelin dye (Servicebio, G1030), Hematoxylin dye (Servicebio, G1004), Eosin dye (Servicebio, G1001), BCA protein concentration determination kit (Boster, AR0146), Antibeta Actin Rabbit pAb (Servicebio, GB11001), Anti-Albumin antibody (Abcam, ab207327), Anti-IL-6 antibody (Abcam, ab259341), Anti-IL-1 beta antibody (Abcam, ab254360), AKT1 Antibody (Abways, CY5551), P53 Monoclonal antibody (Proteintech, 60283–2-Ig), Phospho-AKT (Ser473) monoclonal antibody (Proteintech, 66444–1-Ig), Phospho-P53 (ser315) Monoclonal antibody (Wanleibio, WL02504), Rat Tumor necrosis factor α (TNF-α) ELISA Kit (Bioswamp, RA20035), Rat Interleukin 1β (IL-1β) ELISA Kit (Bioswamp, RA20020), Rat interleukin6 (IL-6) ELISA Kit (Bioswamp, RA20607), Rat Interleukin 17 (IL-17) ELISA Kit (Bioswamp, RA20117), M5 HiPer Universal RNA Mini Kit (Mei5 Biotechnology Co., Ltd, MF036–01), M5 Sprint qPCR RT kit with gDNA remover (Mei5 Biotechnology Co., Ltd, MF949-T), and 2X M5 HiPer SYBR Premix EsTaq (with Tli RNaseH) (Mei5 Biotechnology Co., Ltd, MF787-T).

Techniques: Residue

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Article Title: Elucidating the mechanisms of Buyang Huanwu Decoction in treating chronic cerebral ischemia: A combined approach using network pharmacology, molecular docking, and in vivo validation.

doi: 10.1016/j.phymed.2024.155820

Figure Lengend Snippet: Fig. 9. The expression of AKT1 and TP53 in hippocampal and cortical tissues of CCI rats was detected by immunohistochemistry. (A) Representative micrographs of AKT were detected by immunohistochemistry of the cortex and hippocampus. (B) Representative micrographs of TP53 were detected by immunohistochemistry of the cortex and hippocampus. (C) Quantitative analysis of AKT in cortex and hippocampus. (D) Quantitative analysis of TP53 in cortex and hippocampus. Data are expressed as x ± s, n = 3 rats for each group. #p < 0.05, ##p < 0.01 vs Sham group; *p < 0.05, **p < 0.01 vs Model group.

Article Snippet: The following reagents were used: Nimodipine Tablets (Bayer Healthcare Company Ltd., BJ71756), Methanol (CNW Technologies, CAS: 67–56–1), Acetonitrile (CNW Technologies, CAS: 75–05–8), Formic acid (SIGMA, CAS: 64–18–6), 2-Chloro-L-phenylalanine (Shanghai Hengbai Biotech Co., Ltd, CAS: 103616–89–3), isoflurane (Shenzhen Reward Biotechnology Co., Ltd., R510–22–10), ampicillin sodium (Beijing Solarbio Science & Technology Co., Ltd, A8180), Universal tissue fixative (Servicebio, G1101), HE dye kit (Servicebio, G1003), Nissl staining (Servicebio, G1036), Myelin dye (Servicebio, G1030), Hematoxylin dye (Servicebio, G1004), Eosin dye (Servicebio, G1001), BCA protein concentration determination kit (Boster, AR0146), Antibeta Actin Rabbit pAb (Servicebio, GB11001), Anti-Albumin antibody (Abcam, ab207327), Anti-IL-6 antibody (Abcam, ab259341), Anti-IL-1 beta antibody (Abcam, ab254360), AKT1 Antibody (Abways, CY5551), P53 Monoclonal antibody (Proteintech, 60283–2-Ig), Phospho-AKT (Ser473) monoclonal antibody (Proteintech, 66444–1-Ig), Phospho-P53 (ser315) Monoclonal antibody (Wanleibio, WL02504), Rat Tumor necrosis factor α (TNF-α) ELISA Kit (Bioswamp, RA20035), Rat Interleukin 1β (IL-1β) ELISA Kit (Bioswamp, RA20020), Rat interleukin6 (IL-6) ELISA Kit (Bioswamp, RA20607), Rat Interleukin 17 (IL-17) ELISA Kit (Bioswamp, RA20117), M5 HiPer Universal RNA Mini Kit (Mei5 Biotechnology Co., Ltd, MF036–01), M5 Sprint qPCR RT kit with gDNA remover (Mei5 Biotechnology Co., Ltd, MF949-T), and 2X M5 HiPer SYBR Premix EsTaq (with Tli RNaseH) (Mei5 Biotechnology Co., Ltd, MF787-T).

Techniques: Expressing, Immunohistochemistry

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Article Title: Elucidating the mechanisms of Buyang Huanwu Decoction in treating chronic cerebral ischemia: A combined approach using network pharmacology, molecular docking, and in vivo validation.

doi: 10.1016/j.phymed.2024.155820

Figure Lengend Snippet: Fig. 10. The expression of AKT1 and TP53 in hippocampal and cortical tissues of CCI rats was detected by immunofluorescence. (A) Representative micrographs of AKT were detected by immunofluorescence staining of the cortex and hippocampus. (B) Representative micrographs of TP53 were detected by immunofluorescence staining of the cortex and hippocampus. (C) Relative fluorescence intensity analysis of AKT and TP53 in cortex and hippocampus. Data are expressed as x ± s, n = 3 rats for each group. #p < 0.05, ##p < 0.01 vs Sham group; *p < 0.05, **p < 0.01 vs Model group.

Article Snippet: The following reagents were used: Nimodipine Tablets (Bayer Healthcare Company Ltd., BJ71756), Methanol (CNW Technologies, CAS: 67–56–1), Acetonitrile (CNW Technologies, CAS: 75–05–8), Formic acid (SIGMA, CAS: 64–18–6), 2-Chloro-L-phenylalanine (Shanghai Hengbai Biotech Co., Ltd, CAS: 103616–89–3), isoflurane (Shenzhen Reward Biotechnology Co., Ltd., R510–22–10), ampicillin sodium (Beijing Solarbio Science & Technology Co., Ltd, A8180), Universal tissue fixative (Servicebio, G1101), HE dye kit (Servicebio, G1003), Nissl staining (Servicebio, G1036), Myelin dye (Servicebio, G1030), Hematoxylin dye (Servicebio, G1004), Eosin dye (Servicebio, G1001), BCA protein concentration determination kit (Boster, AR0146), Antibeta Actin Rabbit pAb (Servicebio, GB11001), Anti-Albumin antibody (Abcam, ab207327), Anti-IL-6 antibody (Abcam, ab259341), Anti-IL-1 beta antibody (Abcam, ab254360), AKT1 Antibody (Abways, CY5551), P53 Monoclonal antibody (Proteintech, 60283–2-Ig), Phospho-AKT (Ser473) monoclonal antibody (Proteintech, 66444–1-Ig), Phospho-P53 (ser315) Monoclonal antibody (Wanleibio, WL02504), Rat Tumor necrosis factor α (TNF-α) ELISA Kit (Bioswamp, RA20035), Rat Interleukin 1β (IL-1β) ELISA Kit (Bioswamp, RA20020), Rat interleukin6 (IL-6) ELISA Kit (Bioswamp, RA20607), Rat Interleukin 17 (IL-17) ELISA Kit (Bioswamp, RA20117), M5 HiPer Universal RNA Mini Kit (Mei5 Biotechnology Co., Ltd, MF036–01), M5 Sprint qPCR RT kit with gDNA remover (Mei5 Biotechnology Co., Ltd, MF949-T), and 2X M5 HiPer SYBR Premix EsTaq (with Tli RNaseH) (Mei5 Biotechnology Co., Ltd, MF787-T).

Techniques: Expressing, Immunofluorescence, Staining, Fluorescence

Journal: NeuroImage

Article Title: Adaptive data-driven motion detection and optimized correction for brain PET

doi: 10.1016/j.neuroimage.2022.119031

Figure Lengend Snippet: Detectability and false positive rate results for 3DCOD as a function of α for 18 F-FDG (top) and 11 C-RAC (bottom) simulated for the HRRT scanner.

Article Snippet: The proposed motion correction method was tested on 22 real human datasets, with 20 acquired from a high resolution research tomograph (HRRT) scanner ( 18 F-FDG, N = 10; 11 C-RAC, N = 10) and 2 acquired from the Siemens Biograph mCT scanner.

Techniques:

Journal: NeuroImage

Article Title: Adaptive data-driven motion detection and optimized correction for brain PET

doi: 10.1016/j.neuroimage.2022.119031

Figure Lengend Snippet: Comparison of detectability and false positive rate results between 1DCOD and 3DCOD approaches for simulated 18 F-FDG (top) and 11 C-RAC (bottom) HRRT studies (without TOF). Red line with stars indicates the 3DCOD method. The inflation factor α was set to 1.0 and 1.6 for 18 F-FDG and 11 C-RAC studies, respectively. Each data point in the detectability figures is the ratio between the total number of correctly detected MTPs and the total number of ground-truth MTPs in all the simulated studies at a given motion amplitude.

Article Snippet: The proposed motion correction method was tested on 22 real human datasets, with 20 acquired from a high resolution research tomograph (HRRT) scanner ( 18 F-FDG, N = 10; 11 C-RAC, N = 10) and 2 acquired from the Siemens Biograph mCT scanner.

Techniques: Comparison

Journal: NeuroImage

Article Title: Adaptive data-driven motion detection and optimized correction for brain PET

doi: 10.1016/j.neuroimage.2022.119031

Figure Lengend Snippet: Sample slices of motion-corrected reconstructions of simulated HRRT (A) 18 F-FDG study (60–90 min) and (B) 11 C-RAC study (30–60 min). Studies are ranked 15/15 (worst case) based on mean difference for the 3DCOD-based approach. The best cases (1/15) can be found in .

Article Snippet: The proposed motion correction method was tested on 22 real human datasets, with 20 acquired from a high resolution research tomograph (HRRT) scanner ( 18 F-FDG, N = 10; 11 C-RAC, N = 10) and 2 acquired from the Siemens Biograph mCT scanner.

Techniques:

Journal: NeuroImage

Article Title: Adaptive data-driven motion detection and optimized correction for brain PET

doi: 10.1016/j.neuroimage.2022.119031

Figure Lengend Snippet: Sample slices of motion-corrected reconstructions of a HRRT 11 C-RAC study (black and white colormap: 0–10 min, hot metal: 60–90 min) using (A) Vicra and (B) 3DCOD methods. Vicra shows a clear misalignment between the early and late frames while 3DCOD shows a good alignment.

Article Snippet: The proposed motion correction method was tested on 22 real human datasets, with 20 acquired from a high resolution research tomograph (HRRT) scanner ( 18 F-FDG, N = 10; 11 C-RAC, N = 10) and 2 acquired from the Siemens Biograph mCT scanner.

Techniques:

Journal: NeuroImage

Article Title: Adaptive data-driven motion detection and optimized correction for brain PET

doi: 10.1016/j.neuroimage.2022.119031

Figure Lengend Snippet: Sample slices of motion-corrected reconstructions of a real 18 F-FDG (60–90 min) HRRT study showing the proposed 3DCOD approach compared with NMC, Vicra and COD* (example result from our previous work).

Article Snippet: The proposed motion correction method was tested on 22 real human datasets, with 20 acquired from a high resolution research tomograph (HRRT) scanner ( 18 F-FDG, N = 10; 11 C-RAC, N = 10) and 2 acquired from the Siemens Biograph mCT scanner.

Techniques:

Journal: eLife

Article Title: The chemorepellent, SLIT2, bolsters innate immunity against Staphylococcus aureus

doi: 10.7554/eLife.87392

Figure Lengend Snippet:

Article Snippet: Commercial assay or kit , G-LISA Rac Activation Assay , Cytoskeleton, Inc, Denver, CO, USA , Cat# BK125 , Rac1/2/3 activation assay.

Techniques: Western Blot, Blocking Assay, Flow Cytometry, In Vivo, Injection, Sequencing, Sterility, Bacteria, Electron Microscopy, Isolation, SYBR Green Assay, Real-time Polymerase Chain Reaction, Activation Assay, Recombinant, Staining, Polymer, Enzyme-linked Immunosorbent Assay, Software

Journal: Cell communication and signaling : CCS

Article Title: Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib).

doi: 10.1186/s12964-024-01788-3

Figure Lengend Snippet: Fig. 2 Activation of signaling pathways in resistant and control melanoma cell lines. The level of total or phosphorylated (A) AKT, (B) p38, and (C) JNK in cell lysates was determined using Western blotting analysis. The signal was normalized to the total protein content assessed by Ponceau S staining. Representative blotting membranes of at least three biological repetitions are shown. The expression level of the (D) NRAS and (E) MITF genes was estimated by real-time PCR and with the use of designed primers. HPRT1 constituted a reference gene. Control (CTRL) constitutes WM9 and Hs294T cells treated with regular media with DMSO at the concentration used for drug delivery. The graphs show average values from at least three independent experiments ± SD. Asterisks indicate statistically important differences between tested and control cells. The significance level was set at p ≤ 0.05 (*), p ≤ 0.01 (**), and p ≤ 0.001 (***)

Article Snippet: Primary antibodies were directed against pERK1/2 (phosphorylated extracellular signal-regulated kinases 1/2) (Cell Signaling Technologies, #9101, 1:1000), AKT (Protein kinase B) (Cell Signaling Technologies, #4691, 1:1000), pAKT (phosphorylated protein kinase B) (Cell Signaling Technologies, #9271, 1:1000), p38 (p38 mitogen-activated protein kinase) (Cell Signaling Technologies, #8690, 1:1000), p-p38 (phosphorylated p38 mitogen-activated protein kinase) (Cell Signaling Technologies, #4511, 1:1000), JNK (c-Jun N-terminal kinase) (Santa Cruz Biotechnology, sc-7345, 1:200), p-JNK (phosphorylated c-Jun N-terminal kinase) (Santa Cruz Biotechnology, sc-6254, 1:200), CYP1A1 (Cytochrome P450 family 1 subfamily A member 1) (Santa Cruz Biotechnology, sc-25304, 1:200), ALCAM (CD166 antigen) (Santa Cruz Biotechnology, sc-74558, 1:200), TGFβRIII (Transforming growth factor-beta receptor III) (Cell Signaling Technologies, #2519, 1:1000), TGFβRI (Transforming growth factor-beta receptor I) (Santa Cruz Biotechnology, sc-398, 1:200), SOX2 (SRY-box transcription factor 2) (Cell Signaling Technologies, #3578, 1:1000), CDK6 (cyclin-dependent kinase 6) (Cell Signaling Technologies, #3136, 1:1000), p18 (CDKN2C (cyclin dependent kinase inhibitor 2 C) (Cell Signaling Technologies, #2896, 1:1000), p21 ((CDKN1A) cyclin dependent kinase inhibitor 1 A) (Cell Signaling Technologies, #2947, 1:1000), and p27 ((CDKN1B) cyclin dependent kinase inhibitor 1B) (Cell Signaling Technologies, #3686, 1:1000).

Techniques: Activation Assay, Protein-Protein interactions, Control, Western Blot, Staining, Expressing, Real-time Polymerase Chain Reaction, Concentration Assay